Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Gain Therapeutics announced significant progress in its development of rexaceract, a potentially first-in-category therapy targeting Parkinson’s disease. The company reported encouraging Phase 1b data demonstrating safety, tolerability, and biomarker evidence supporting disease modification. With IND authorization received, Gain plans to initiate a…